Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

217691 CDC25 Phosphatase Inhibitor I, BN82002 - CAS 396073-89-5 - Calbiochem

217691
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₁₉H₂₅N₃O₄396073-89-5

Products

Catalogue NumberPackaging Qty/Pack
217691-5MG Plastic ampoule 5 mg
Description
OverviewA cell-permeable ortho-hydroxybenzylamino compound that displays antitumor properties. Acts as a potent, selective and irreversible inhibitor of CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases over CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC50 = ~7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cells MIA PaCa-2 (15 mg/kg, i.p. route).
Catalogue Number217691
Brand Family Calbiochem®
SynonymsN-(2-Hydroxy-3-methoxy-5-dimethylamino)benzyl, Nʹ-(2-(4-nitrophenethyl)), Nʹʹ-methylamine, PTP Inhibitor XX
References
ReferencesBrezak, M.C., et al. 2004. Cancer Res. 64, 3320.
Product Information
CAS number396073-89-5
ATP CompetitiveN
FormRed to dark red solid
Hill FormulaC₁₉H₂₅N₃O₄
Chemical formulaC₁₉H₂₅N₃O₄
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetCDC25A
Primary Target IC<sub>50</sub>2.4, 3.9, 6.3, 5.4, and 4.6 µM for CDC25 phosphatase family 25A, 25B2, 25B3, 25C, and 25C-cat, respectively
Purity≥95% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Unstable in aqueous solution.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

CDC25 Phosphatase Inhibitor I, BN82002 - CAS 396073-89-5 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

CDC25 Phosphatase Inhibitor I, BN82002 - CAS 396073-89-5 - Calbiochem Certificates of Analysis

TitleLot Number
217691

References

Reference overview
Brezak, M.C., et al. 2004. Cancer Res. 64, 3320.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision24-June-2019 JSW
SynonymsN-(2-Hydroxy-3-methoxy-5-dimethylamino)benzyl, Nʹ-(2-(4-nitrophenethyl)), Nʹʹ-methylamine, PTP Inhibitor XX
DescriptionA cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. Acts as a potent, selective, and irreversible inhibitor of CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases compared to CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC50 in the range of 7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cell MIA PaCa-2 (15 mg/kg, i.p. route).
FormRed to dark red solid
Intert gas (Yes/No) Packaged under inert gas
CAS number396073-89-5
Chemical formulaC₁₉H₂₅N₃O₄
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (10 mg/ml) or Ethanol (10 mg/ml)
Storage -20°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Unstable in aqueous solution.
Toxicity Standard Handling
ReferencesBrezak, M.C., et al. 2004. Cancer Res. 64, 3320.